BRISTOL MYERS SQUIBB
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
ELIQUIS (APIXABAN) Regulatory Post-Marketing Surveillance In Clinical Practice for Venous Thromboembolism (VTE) Treatment and Prevention Of Recurrent VTE
Completed
- Conditions
- Venous Thromboembolism
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2022-02-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1134
- Registration Number
- NCT02836457
- Locations
- 🇯🇵
Local Institution, Shinjuku-ku, Tokyo, Japan
An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
Phase 2
Completed
- Conditions
- Cancer
- Interventions
- Biological: Nivolumab
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 239
- Registration Number
- NCT02832167
- Locations
- 🇺🇸
Cancer Center of Santa Barbara with Sansum Clinic, Santa Barbara, California, United States
🇺🇸Memorial Healthcare System, Hollywood, Florida, United States
🇺🇸Florida Cancer Specialists, West Palm Beach, Florida, United States
The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2016-12-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT02832180
- Locations
- 🇺🇸
Covance Evansville Clinical Research Unit, Evansville, Indiana, United States
🇺🇸Miami Research Associates, Miami, Florida, United States
A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
Phase 1
Terminated
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Biological: BMS-986183Biological: Nivolumab
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT02828124
- Locations
- 🇨🇳
Local Institution, Taipei, Taiwan
Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 2
Completed
- Conditions
- Head and Neck Cancer
- Interventions
- Biological: NivolumabBiological: IpilimumabOther: Placebo
- First Posted Date
- 2016-07-06
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 425
- Registration Number
- NCT02823574
- Locations
- 🇺🇸
Local Institution - 0087, Chicago, Illinois, United States
🇨🇦Local Institution - 0014, Quebec, Canada
🇧🇪Local Institution - 0023, Gent, Belgium
A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers
Phase 1
Completed
- Conditions
- Heart Failure
- Interventions
- Drug: CXL-1427 Ascending DoseOther: PlaceboDrug: CXL-1427 Descending Dose
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 80
- Registration Number
- NCT02819271
Trial of BMS-986012 in Combination With Platinum and Etoposide
Phase 1
Active, not recruiting
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 12
- Registration Number
- NCT02815592
- Locations
- 🇪🇸
Local Institution - 0002, Barcelona, Spain
🇪🇸Local Institution - 0004, Madrid, Spain
🇪🇸Local Institution - 0010, Malaga, Spain
A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Pharmacokinetics of BMS-986177 in Healthy Subjects
Phase 1
Completed
- Conditions
- Thrombosis
- Interventions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2016-09-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 28
- Registration Number
- NCT02807909
Interferon Toxicities in Melanoma Treatment
Completed
- Conditions
- Stage III Melanoma
- First Posted Date
- 2016-06-09
- Last Posted Date
- 2016-06-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 436
- Registration Number
- NCT02794636
Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 28000
- Registration Number
- NCT02792335
© Copyright 2025. All Rights Reserved by MedPath